Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients

Leukemia

Volumn 24, Issue 1, 2010, Pages 66-73

  Iacobucci, I ^a   Lonetti, A ^a   Messa, F ^b   Ferrari, A ^a   Cilloni, D ^b   Soverini, S ^a   Paoloni, F ^c   Arruga, F ^b   Ottaviani, E ^a   Chiaretti, S ^d   Messina, M ^d   Vignetti, M ^c   Papayannidis, C ^a   Vitale, A ^d   Pane, F ^e   Piccaluga, P P ^a   Paolini, S ^a   Berton, G ^f   Baruzzi, A ^f   Saglio, G ^b   Baccarani, M ^a   Fo, R ^d   Martinelli, G ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c GIMEMA Foundation   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

Author keywords

AID; ALL; BCR ABL1

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; IMMUNOGLOBULIN G; ISOENZYME; PROTEIN TYROSINE KINASE INHIBITOR; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER RELAPSE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME LOCALIZATION; EXON; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 74249101770     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.197     Document Type: Article

References (36)

1. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001; 15: 21-36.
2. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-1354.
3. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
4. Itoh K, Friel J, Kluge N, Kina T, Kondo-Takaori A, Kawamata S et al. A novel hematopoietic multilineage clone, Myl-D-7, is stromal cell-dependent and supported by an alternative mechanism(s) independent of stem cell factor/c-kit interaction. Blood 1996; 87: 3218-3228.
5. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci USA 2008; 105: 6708-6713.
6. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med 2007; 204: 1157-1166.
7. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999; 274: 18470-18476.
8. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 2002; 20: 165-196.
9. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-563.
10. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000; 102: 565-575.
11. Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, Goodman MF et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 2008; 26: 481-511.
12. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007; 76: 1-22.
13. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R et al. Expression of the AID protein in normal and neoplastic B cells. Blood 2004; 104: 3318-3325.
14. Greeve J, Philipsen A, Krause K, Klapper W, Heidorn K, Castle BE et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003; 101: 3574-3580.
15. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008; 451: 841-845.
16. Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 2003; 102: 3333-3339.
17. Babbage G, Garand R, Robillard N, Zojer N, Stevenson FK, Sahota SS. Mantle cell lymphoma with t(11;14) and unmutated or mutated VH genes expresses AID and undergoes isotype switch events. Blood 2004; 103: 2795-2798.
18. Wu X, Darce JR, Chang SK, Nowakowski GS, Jelinek DF. Alternative splicing regulates activation-induced cytidine deami-nase (AID): implications for suppression of AID mutagenic activity in normal and malignant B cells. Blood 2008; 112: 4675-4682.
19. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N et al. Long-term outcome of complete cytogenetic responders after imatinib 400mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008; 26: 106-111.
20. Esperou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003; 31: 909-918.
21. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006; 12: 3037-3042.
22. Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008; 112: 3847-3855.
23. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
24. Gooley TA, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
25. Simon R, Lee Y. Nonparametric confidence limits survival probabilities and median survival time. Cancer Treat Res 1982; 66: 37-42.
26. Ito S, Nagaoka H, Shinkura R, Begum N, Muramatsu M, Nakata M et al. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci USA 2004; 101: 1975-1980.
27. Wu X, Geraldes P, Platt JL, Cascalho M. The double-edged sword of activation-induced cytidine deaminase. J Immunol 2005; 174: 934-941.
28. Marr S, Morales H, Bottaro A, Cooper M, Flajnik M, Robert J. Localization and differential expression of activation-induced cytidine deaminase in the amphibian Xenopus upon antigen stimulation and during early development. J Immunol 2007; 179: 6783-6789.
29. Larijani M, Frieder D, Sonbuchner TM, Bransteitter R, Goodman MF, Bouhassira EE et al. Methylation protects cytidines from AID-mediated deamination. Mol Immunol 2005; 42: 599-604.
30. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematolo-giche dell' Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676-3678.
31. Foà R, Vitale A, Meloni G, Guarini A, De Propris S, Elia L et al. Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205. Blood 2007; 110: 10a.
32. Foà R, Vitale A, Guarini A, De Propris MS, Elia L, Cimino G et al. Dasatinib monotherapy as 1st line treatment of Ph acute lymphoblastic leukemia (ALL) patients: update of Gimema LAL1205 study. Haematologica 2008; 93 (s1): 367.
33. Wang CL, Harper RA, Wabl M. Genome-wide somatic hyper-mutation. Proc Natl Acad Sci USA 2004; 101: 7352-7356.
34. Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, Zarrin AA et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell 2006; 21: 201-214.
35. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008; 452: 116-119.
36. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006; 103: 6688-6693.